Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
Authors
John Foley (ORCID: https://orcid.org/0000-0003-0431-7067)
Ivan Božin (ORCID: https://orcid.org/0009-0008-2205-4233)
Yang Mao‐Draayer (ORCID: https://orcid.org/0000-0001-6248-3480)
Erin E. Longbrake (ORCID: https://orcid.org/0000-0002-1179-3937)
Konstantin Balashov (ORCID: https://orcid.org/0000-0003-3409-8731)
Jason P. Mendoza (ORCID: https://orcid.org/0000-0003-2526-5542)
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
John Foley, Ivan Božin, Yang Mao‐Draayer, Erin E. Longbrake et al.
Citations
4 citations
Journal
Advances in Therapy
Topics
Multiple Sclerosis Research Studies
Field-Weighted Citation Impact (FWCI)
1.70
article
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
John Foley, Ivan Božin, Yang Mao‐Draayer, Erin E. Longbrake, Konstantin Balashov, Jason P. Mendoza, Derrick Robertson, Eris Bame, Jennifer Lyons, Oksana Mokliatchouk, Amit Bar‐Or, James B. Lewin, Fabrizio Giuliani, Nicholas Everage, Kyle Smoot
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
Advances in TherapyVol. 42(1)
Institutions
Biogen (United States) (US), University of Alberta (CA), Providence College (US), University of South Florida (US), Oklahoma Medical Research Foundation (US), Yale University (US), Rocky Mountain Multiple Sclerosis Clinic (US), Biogen (Switzerland) (CH), University of Pennsylvania (US), University of Genoa (IT), Florida College (US)